Geneva, April 20 -- International Clinical Trials Registry received information related to the study (NCT07524530) titled 'Phase II Haploidentical Hematopoietic Stem Cell Transplantation for Participants With Germline RUNX1 Associated Hematologic Malignancies' on April 10.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: National Cancer Institute (NCI)
Condition:
Core Binding Factor Alpha Subunits
Hematologic Neoplasms
Leukemia
Lymphoma
Intervention:
Drug: Cyclophosphamide
Drug: Busulfan
Drug: Fludarabine
Radiation: Total Body Irradiation
Biological: Hematopoietic stem cells
Drug: Tacrolimus
Recrui...